Agalimmune Ltd. Report issue

For profit Phase 2
Founded: Irvine CA United States (2013)
Status: Acquired by BioLineRx, Ltd. (2011)

Organization Overview

First Clinical Trial
2018
NCT03593226
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Agalimmune Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

agi-134 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1